GlassScriptPhysician profile
Gerard M Roy
NPI 1992775910
$5,781.41
in general payments reported to CMS, 2019-2025
31 companies · $872 in 2025
The $872 reported for 2025 was more than what 89% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $710 · 2020: $294 · 2021: $994 · 2022: $1,019 · 2023: $960 · 2024: $932 · 2025: $872.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,764.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,764.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,205.14 | 2019-2025 | Lo Loestrin Fe, Orilissa, Liletta |
| Exeltis, USA INC. | $522.34 | 2019-2025 | Slynd |
| Sumitomo Pharma America, INC. | $421.98 | 2023-2025 | Myfembree, Gemtesa |
| Astellas Pharma US INC | $384.68 | 2021-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $371.33 | 2019-2024 | |
| Coopersurgical, INC. | $334.88 | 2020-2025 | Paragard T 380a, Paragard T 380a |
| Agile Therapeutics, INC. | $284.66 | 2021-2024 | Twirla |
| Merck Sharp & Dohme LLC | $274.13 | 2021-2025 | Gardasil 9, Gardasil |
| Lupin INC. | $199.69 | 2019-2021 | |
| Millicent US INC | $198.00 | 2019-2025 | Femlyv, Intrarosa, Femring |
| Therapeuticsmd, INC. | $196.87 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $183.78 | 2021-2025 | |
| Exact Sciences Corporation | $154.08 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Mylan Pharmaceuticals INC. | $141.96 | 2019-2021 | |
| Sage Therapeutics, LLC | $123.89 | 2024-2025 | Zurzuvae |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $108.34 | 2021-2025 | |
| Urovant Sciences INC | $105.59 | 2021-2022 | |
| Duchesnay USA Incorporated | $97.75 | 2019 | |
| Organon LLC | $93.23 | 2021-2025 | |
| Amag Pharmaceuticals, INC. | $92.16 | 2019-2020 | |
| Aspira Women'S Health INC | $77.13 | 2019-2025 | Ova1 |
| Daiichi Sankyo INC. | $48.94 | 2019-2024 | Injectafer |
| Ge Healthcare | $21.74 | 2025 | |
| Evofem Biosciences, INC. | $21.11 | 2021 | |
| Shield Therapeutics INC | $20.96 | 2025 | |
| Boston Scientific Corporation | $20.60 | 2024 | Solyx Sis System |
| Conmed Corporation | $18.43 | 2025 | Airseal |
| Supernus Pharmaceuticals, INC. | $15.48 | 2025 | Qelbree |
| Monaghan Medical Corporation | $14.64 | 2023 | Aerobika |
| Avion Pharmaceuticals | $14.31 | 2021 | |
| Innovation Technologies INC | $13.59 | 2025 | Irrisept |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerard Roy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.